Pick 2–10 funds, stocks or ETFs to see their returns, risk, costs and highlights on one page
* Fewer than 12 months: the year the fund started reporting NAV, or the current year
Counts only the top holdings with available data, not the whole portfolio · Pick a pair below for details
| SCBGENOME(E) | BCARERMF | |
|---|---|---|
| Only in SCBGENOME(E) | ||
 Twist Bioscience | 10.03% | N/A |
 10x Genomics | 8.02% | N/A |
 Tempus AI | 7.15% | N/A |
 CRISPR Therapeutics | 4.20% | N/A |
| Only in BCARERMF | ||
 Eli Lilly and Co | N/A | 8.45% |
 Merck & | N/A | 5.47% |
 Johnson & Johnson | N/A | 4.77% |
 AstraZeneca | N/A | 3.88% |
30 Dec 2025 → 3 Nov 2026
| Fund | Return per year | Volatility per year | Sharpe |
|---|---|---|---|
| SCBGENOME(E) | +69.55% | 42.54% | 1.63 |
| BCARERMF | +14.73% | 15.92% | 0.93 |
Sharpe here = annual return ÷ annual volatility, without deducting the risk-free rate, calculated from NAV over the selected period · Periods shorter than 1 year use the cumulative return instead of the annual return
| Drag a column header to reorder | SCBGENOME(E) | BCARERMF |
|---|---|---|
Fund details | ||
| Fund size | 47.46 million | 8,589 million |
| Inception date | 20 Aug 2021 | 19 May 2015 |
| Master fund | กองทุน ARK Genomic Revolution ETF | Wellington Global Health Care Equity Fund |
| Dividend policy | Does not pay | Does not pay |
Risk and currency hedging | ||
| Risk level | 7 | 7 |
| Hedging policy | Hedged at the manager's discretion | Hedged at the manager's discretion |
| Share hedged | 57.68% | 45.53% |
Minimum purchase and redemption | ||
| First purchase | 1 THB | 500 THB |
| Subsequent purchase | 1 THB | 500 THB |
| Redemption (amount) | 1 THB | No minimum |
| Redemption (units) | No minimum | No minimum |
| Balance (amount) | 1 THB | No minimum |
| Balance (units) | No minimum | No minimum |
Order cut-off and redemption payment | ||
| Buy before | 15:30 | 15:30 |
| Redeem before | 15:30 | 15:30 |
| Redemption paid | T+4 | T+4 |
